Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
J Matern Fetal Neonatal Med ; 25(12): 2782-5, 2012 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-22882154

RESUMO

OBJECTIVE: To compare the efficacy of intravenous immunoglobulin (IVIg) and exchange transfusion (EXT) on rhesus haemolytic disease of the newborn (Rh-HDN) and evaluate treatment-related side effects. METHODS: Retrospective chart review of two cohorts of newborns with Rh-HDN, treated with (Group 2) or without (Group 1) IVIg. Length of phototherapy, number of EXT, IVIg infusions, intrauterine and top-up red blood cells transfusions, need and permanence of umbilical venous catheter, and length of hospital stay, as well as treatment-related adverse events, were evaluated. RESULTS: Charts of 88 newborns were reviewed (34 in Group 1, 54 in Group 2). Infants in Group 2 received a significantly lower number of EXT, had a lower risk of neurological impairment and needed an umbilical venous catheter for shorter, but required longer phototherapy, longer length of hospital stay, and more top-up transfusions. EXT was associated with a high number of adverse events. Two newborns treated with IVIg developed necrotizing enterocolitis (NEC). CONCLUSIONS: IVIg appear as an effective alternative to EXT, reducing the risk of neurological impairment and complications related to EXT. However, side effects of IVIg treatment (higher need of top-up transfusions and longer hospital stay) should be taken into account and the risk of NEC should be carefully monitored during treatment.


Assuntos
Eritroblastose Fetal/terapia , Imunoglobulinas Intravenosas/uso terapêutico , Anemia Hemolítica Autoimune/epidemiologia , Anemia Hemolítica Autoimune/terapia , Peso ao Nascer/fisiologia , Estudos de Coortes , Enterocolite Necrosante/epidemiologia , Enterocolite Necrosante/etiologia , Eritroblastose Fetal/epidemiologia , Transfusão Total , Feminino , Idade Gestacional , Humanos , Imunização Passiva/efeitos adversos , Imunoglobulinas Intravenosas/efeitos adversos , Recém-Nascido , Masculino , Estudos Retrospectivos , Isoimunização Rh/epidemiologia , Isoimunização Rh/terapia , Resultado do Tratamento
2.
J Matern Fetal Neonatal Med ; 25(12): 2735-8, 2012 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-22725606

RESUMO

BACKGROUND: Gastro-oesophageal reflux (GOR) is common in preterm infants; conservative interventions (i.e. dietary changes) should represent the first-line approach. AIM: To evaluate by combined pH and impedance monitoring (pH-MII) the effect of a new preterm formula thickened with amylopectin (TPF) on GOR features in symptomatic preterm infants. METHODS: Twenty-eight symptomatic preterm newborns underwent a 24-hour pH-MII; each baby received eight meals (four of TPF and four of a preterm formula [PF]). GOR indexes (number, acidity, duration and height of GORs) after TPF and PF meals were compared by Wilcoxon Signed Ranks Test. Viscosity of PF and TPF was measured. RESULTS: TPF significantly decreased the number of acid GORs detected by pH-monitoring (TPF vs. PF: median 20 vs. 24.5, p = 0.009), while it had no influence on Reflux Index (RIpH), nor on acid and non-acid GOR indexes detected by MII, GOR physical features, and GOR height. TPF's viscosity was extremely higher than PF's, and further increased at pH 3 after the addition of pepsin. CONCLUSIONS: The new formula was found to reduce the number of acid GORs detected by pH-monitoring; it did not reduce neither total oesophageal acid exposure nor non-acid GORs. At present its extended clinical use cannot be recommended.


Assuntos
Refluxo Gastroesofágico/dietoterapia , Fórmulas Infantis/administração & dosagem , Doenças do Prematuro/dietoterapia , Amido/administração & dosagem , Suplementos Nutricionais , Impedância Elétrica , Esôfago/química , Esôfago/metabolismo , Esôfago/fisiopatologia , Feminino , Alimentos Fortificados , Refluxo Gastroesofágico/congênito , Refluxo Gastroesofágico/diagnóstico , Refluxo Gastroesofágico/metabolismo , Idade Gestacional , Humanos , Concentração de Íons de Hidrogênio , Recém-Nascido , Recém-Nascido Prematuro , Doenças do Prematuro/diagnóstico , Masculino , Projetos Piloto , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA